. 2021 Oct 16;43(2):681–699. doi: 10.1002/hbm.25679

TABLE 1.

Sample characteristics

	ALS		HC		STATS
	N = 97		N = 59		STATS
	Mean/N	SD/%	Mean/N	SD/%	Test‐statistic	dof	p
Age at MRI (years)	57.92	11.1 ^c	55.06	10.6 ^c	1.59 ^a	154	.114
Gender
Male	60	61.9 ^d	30	50.8 ^d	0.64 ^b		.186
Female	37	38.1 ^d	29	49.2 ^d
Handedness
Right	89	91.8 ^d	54	91.5 ^d
Left	8	8.2 ^d	5	8.5 ^d
Onset‐type
Bulbar	28	28.9 ^d
Limb	69	71.1 ^d
Riluzole intake at MRI
Yes	80	82.5 ^d
No	17	17.5 ^d
Relevant riluzole intake during the disease course (>50%)
Yes	78	80.4 ^d
No	19	19.6 ^d
Age at symptom onset (years)	56.4	11.0 ^c
Symptom duration (months)	18.59	17.98 ^c
ALSFRS‐R total score (points)	39.15	6.09 ^c
Progression rate (points lost per month)	0.65	0.53 ^c
D50 (months)	41.29	39.84 ^c
rD50	0.25	0.1 ^c
Phase
I	50	51.5 ^d
II	47	48.5 ^d
cFL (points lost per month)	0.91	0.9 ^c
cFS (points)	38.99	5.8 ^c

Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS‐R, ALS Functional Rating Scale Revised; cFL, calculated functional loss; cFS, calculated functional state at the time point of scanning; dof, degrees of freedom; D50, overall disease aggressiveness; HC, healthy controls; MRI, magnetic resonance imaging; rD50, relative disease aggressiveness; SD, standard deviation; p, p‐value.

^{^a}

T‐value.

^{^b}

Odds ratio.

^{^c}

Standard deviation.

^{^d}